Fig. 3.

Treatment with RBC-thrombomodulin rescues the thrombotic phenotype of Erg^iEC-KO mice. a, b qPCR analysis of ERG, CD31 and TM gene expression in whole a liver and b lung lysates from adult control (Erg^fl/fl) and ERG-deficient (Erg^iEC-KO) mice (n = 3); 25 days after tamoxifen injection and 6 h after RBC-TM injection. Data were normalized to 18S. Graphical data are mean ± s.e.m., *P < 0.05, Student’s t-test. c–e Adult Erg^iEC-KO and control mice were bled before and after (6 h) injection of red blood cells-targeted thrombomodulin (RBC-TM, 4 mg per kg) to analyse plasma markers for coagulopathy. a Thrombin-antithrombin (TAT) complex concentration (ng per µL) was measured on plasma from Erg^iEC-KO and Erg^fl/fl mice, using mouse TAT ELISA kit (n = 3–4 per genotype). b D-dimer concentration (ng per mL) was measured on plasma from Erg^iEC-KO and Erg^fl/fl mice, using mouse D-dimer ELISA kit (n = 3–4 per genotype). c Fibrinogen concentration (µg per mL) was measured on plasma from Erg^iEC-KO and Erg^fl/fl mice, using mouse Fibrinogen ELISA kit (n = 3–4 per genotype). All graphical data are mean ± s.e.m., NS: Not significant, *P < 0.05, **P < 0.01, Student’s t-test. Data for each Erg^iEC-KO mouse before and after RBC-TM injection are also presented in separated graphs (bottom graphs) to see individual response to the treatment. Source data are provided as a Source Data file